Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience

Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, Shoichi Kuyama, Yoshihiko Segawa, Toshiro Yonei, Kenichi Gemba, Keisuke Aoe, Takuo Shibayama, Keisuke Matsuo, Haruhito Kamei, Yoshiro Fujiwara, Akihiko Bessho, Tomonori Moritaka, Keisuke Sugimoto, Masahiro Tabata, Hiroshi Ueoka, Mitsune Tanimoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Gefitinib is effective in patients with lung adenocarcinoma. Smoking status also affects the responsiveness to gefitinib, but it has not been fully evaluated whether a sex difference exists in the influence of smoking on the efficacy of gefitinib in patients with lung adenocarcinoma. Methods: We reviewed the clinical records of 260 Japanese patients with lung adenocarcinoma who received gefitinib therapy (250 mg/day), and whose smoking status was known. Tumour response and survival were evaluated and stratified by smoking status and gender. Results: Among the 260 patients, 157 were male (60%). Median pack-years was 40 (range 8-160) and 23 (range 1-74) in male and female smokers, respectively. Objective response was observed in 62 (23.8%) of the 260 patients, and 1-year overall survival and progression-free survival were 45.1 and 24.3%, respectively. Multivariate analysis revealed that smoking status (pack-years) was an independent predictive factor for response to gefitinib [odds ratio (OR) = 0.971, 95% confidence interval (CI) = 0.947-0.995; P = 0.0159] in male patients, but not in female patients (OR = 0.999, 95%CI = 0.957-1.042). Additionally, pack-years significantly influenced the overall survival in males (hazard ratio = 1.010; 95%CI = 1.002-1018, P = 0.0169), while differential survival of females was not significantly predicted by this factor (P = 0.7639). Conclusions: In male patients with lung adenocarcinoma, cumulative smoking significantly affected response and survival following gefitinib treatment, while in female patients, responsiveness to gefitinib was independent of smoking status. These results suggest that the influence of smoking habit on responsiveness to gefitinib is gender specific.

Original languageEnglish
Pages (from-to)117-123
Number of pages7
JournalJournal of Cancer Research and Clinical Oncology
Volume135
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Sex Characteristics
Lung Neoplasms
Smoking
Survival
Confidence Intervals
Odds Ratio
gefitinib
Adenocarcinoma of lung
Disease-Free Survival
Habits
Multivariate Analysis
Therapeutics

Keywords

  • Gefitinib
  • Gender
  • Non-small-cell lung cancer
  • Objective response
  • Smoking status

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung : Okayama Lung Cancer Study Group experience. / Hotta, Katsuyuki; Kiura, Katsuyuki; Takigawa, Nagio; Kuyama, Shoichi; Segawa, Yoshihiko; Yonei, Toshiro; Gemba, Kenichi; Aoe, Keisuke; Shibayama, Takuo; Matsuo, Keisuke; Kamei, Haruhito; Fujiwara, Yoshiro; Bessho, Akihiko; Moritaka, Tomonori; Sugimoto, Keisuke; Tabata, Masahiro; Ueoka, Hiroshi; Tanimoto, Mitsune.

In: Journal of Cancer Research and Clinical Oncology, Vol. 135, No. 1, 01.2009, p. 117-123.

Research output: Contribution to journalArticle

Hotta, K, Kiura, K, Takigawa, N, Kuyama, S, Segawa, Y, Yonei, T, Gemba, K, Aoe, K, Shibayama, T, Matsuo, K, Kamei, H, Fujiwara, Y, Bessho, A, Moritaka, T, Sugimoto, K, Tabata, M, Ueoka, H & Tanimoto, M 2009, 'Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience', Journal of Cancer Research and Clinical Oncology, vol. 135, no. 1, pp. 117-123. https://doi.org/10.1007/s00432-008-0431-1
Hotta, Katsuyuki ; Kiura, Katsuyuki ; Takigawa, Nagio ; Kuyama, Shoichi ; Segawa, Yoshihiko ; Yonei, Toshiro ; Gemba, Kenichi ; Aoe, Keisuke ; Shibayama, Takuo ; Matsuo, Keisuke ; Kamei, Haruhito ; Fujiwara, Yoshiro ; Bessho, Akihiko ; Moritaka, Tomonori ; Sugimoto, Keisuke ; Tabata, Masahiro ; Ueoka, Hiroshi ; Tanimoto, Mitsune. / Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung : Okayama Lung Cancer Study Group experience. In: Journal of Cancer Research and Clinical Oncology. 2009 ; Vol. 135, No. 1. pp. 117-123.
@article{979051768ff042bc9200ddf6214be34c,
title = "Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience",
abstract = "Background: Gefitinib is effective in patients with lung adenocarcinoma. Smoking status also affects the responsiveness to gefitinib, but it has not been fully evaluated whether a sex difference exists in the influence of smoking on the efficacy of gefitinib in patients with lung adenocarcinoma. Methods: We reviewed the clinical records of 260 Japanese patients with lung adenocarcinoma who received gefitinib therapy (250 mg/day), and whose smoking status was known. Tumour response and survival were evaluated and stratified by smoking status and gender. Results: Among the 260 patients, 157 were male (60{\%}). Median pack-years was 40 (range 8-160) and 23 (range 1-74) in male and female smokers, respectively. Objective response was observed in 62 (23.8{\%}) of the 260 patients, and 1-year overall survival and progression-free survival were 45.1 and 24.3{\%}, respectively. Multivariate analysis revealed that smoking status (pack-years) was an independent predictive factor for response to gefitinib [odds ratio (OR) = 0.971, 95{\%} confidence interval (CI) = 0.947-0.995; P = 0.0159] in male patients, but not in female patients (OR = 0.999, 95{\%}CI = 0.957-1.042). Additionally, pack-years significantly influenced the overall survival in males (hazard ratio = 1.010; 95{\%}CI = 1.002-1018, P = 0.0169), while differential survival of females was not significantly predicted by this factor (P = 0.7639). Conclusions: In male patients with lung adenocarcinoma, cumulative smoking significantly affected response and survival following gefitinib treatment, while in female patients, responsiveness to gefitinib was independent of smoking status. These results suggest that the influence of smoking habit on responsiveness to gefitinib is gender specific.",
keywords = "Gefitinib, Gender, Non-small-cell lung cancer, Objective response, Smoking status",
author = "Katsuyuki Hotta and Katsuyuki Kiura and Nagio Takigawa and Shoichi Kuyama and Yoshihiko Segawa and Toshiro Yonei and Kenichi Gemba and Keisuke Aoe and Takuo Shibayama and Keisuke Matsuo and Haruhito Kamei and Yoshiro Fujiwara and Akihiko Bessho and Tomonori Moritaka and Keisuke Sugimoto and Masahiro Tabata and Hiroshi Ueoka and Mitsune Tanimoto",
year = "2009",
month = "1",
doi = "10.1007/s00432-008-0431-1",
language = "English",
volume = "135",
pages = "117--123",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung

T2 - Okayama Lung Cancer Study Group experience

AU - Hotta, Katsuyuki

AU - Kiura, Katsuyuki

AU - Takigawa, Nagio

AU - Kuyama, Shoichi

AU - Segawa, Yoshihiko

AU - Yonei, Toshiro

AU - Gemba, Kenichi

AU - Aoe, Keisuke

AU - Shibayama, Takuo

AU - Matsuo, Keisuke

AU - Kamei, Haruhito

AU - Fujiwara, Yoshiro

AU - Bessho, Akihiko

AU - Moritaka, Tomonori

AU - Sugimoto, Keisuke

AU - Tabata, Masahiro

AU - Ueoka, Hiroshi

AU - Tanimoto, Mitsune

PY - 2009/1

Y1 - 2009/1

N2 - Background: Gefitinib is effective in patients with lung adenocarcinoma. Smoking status also affects the responsiveness to gefitinib, but it has not been fully evaluated whether a sex difference exists in the influence of smoking on the efficacy of gefitinib in patients with lung adenocarcinoma. Methods: We reviewed the clinical records of 260 Japanese patients with lung adenocarcinoma who received gefitinib therapy (250 mg/day), and whose smoking status was known. Tumour response and survival were evaluated and stratified by smoking status and gender. Results: Among the 260 patients, 157 were male (60%). Median pack-years was 40 (range 8-160) and 23 (range 1-74) in male and female smokers, respectively. Objective response was observed in 62 (23.8%) of the 260 patients, and 1-year overall survival and progression-free survival were 45.1 and 24.3%, respectively. Multivariate analysis revealed that smoking status (pack-years) was an independent predictive factor for response to gefitinib [odds ratio (OR) = 0.971, 95% confidence interval (CI) = 0.947-0.995; P = 0.0159] in male patients, but not in female patients (OR = 0.999, 95%CI = 0.957-1.042). Additionally, pack-years significantly influenced the overall survival in males (hazard ratio = 1.010; 95%CI = 1.002-1018, P = 0.0169), while differential survival of females was not significantly predicted by this factor (P = 0.7639). Conclusions: In male patients with lung adenocarcinoma, cumulative smoking significantly affected response and survival following gefitinib treatment, while in female patients, responsiveness to gefitinib was independent of smoking status. These results suggest that the influence of smoking habit on responsiveness to gefitinib is gender specific.

AB - Background: Gefitinib is effective in patients with lung adenocarcinoma. Smoking status also affects the responsiveness to gefitinib, but it has not been fully evaluated whether a sex difference exists in the influence of smoking on the efficacy of gefitinib in patients with lung adenocarcinoma. Methods: We reviewed the clinical records of 260 Japanese patients with lung adenocarcinoma who received gefitinib therapy (250 mg/day), and whose smoking status was known. Tumour response and survival were evaluated and stratified by smoking status and gender. Results: Among the 260 patients, 157 were male (60%). Median pack-years was 40 (range 8-160) and 23 (range 1-74) in male and female smokers, respectively. Objective response was observed in 62 (23.8%) of the 260 patients, and 1-year overall survival and progression-free survival were 45.1 and 24.3%, respectively. Multivariate analysis revealed that smoking status (pack-years) was an independent predictive factor for response to gefitinib [odds ratio (OR) = 0.971, 95% confidence interval (CI) = 0.947-0.995; P = 0.0159] in male patients, but not in female patients (OR = 0.999, 95%CI = 0.957-1.042). Additionally, pack-years significantly influenced the overall survival in males (hazard ratio = 1.010; 95%CI = 1.002-1018, P = 0.0169), while differential survival of females was not significantly predicted by this factor (P = 0.7639). Conclusions: In male patients with lung adenocarcinoma, cumulative smoking significantly affected response and survival following gefitinib treatment, while in female patients, responsiveness to gefitinib was independent of smoking status. These results suggest that the influence of smoking habit on responsiveness to gefitinib is gender specific.

KW - Gefitinib

KW - Gender

KW - Non-small-cell lung cancer

KW - Objective response

KW - Smoking status

UR - http://www.scopus.com/inward/record.url?scp=56649123403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56649123403&partnerID=8YFLogxK

U2 - 10.1007/s00432-008-0431-1

DO - 10.1007/s00432-008-0431-1

M3 - Article

C2 - 18618142

AN - SCOPUS:56649123403

VL - 135

SP - 117

EP - 123

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 1

ER -